1.00Open1.00Pre Close0 Volume6 Open Interest7.50Strike Price0.00Turnover640.09%IV185.23%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type0.5525Delta0.0888Gamma2.98Leverage Ratio-0.0450Theta0.0004Rho1.65Eff Leverage0.0028Vega
CASI Pharmaceuticals Stock Discussion
📊⚡️📊
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals (NASDAQ:CASI) has received Clinical Trial Application (CTA) approval from China's NMPA to conduct a phase 1/2 study of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP). The China study is part of a global study previously approved by the US FDA in May 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that...
$MicroCloud Hologram (HOLO.US)$ $Loop Media (LPTV.US)$ $CASI Pharmaceuticals (CASI.US)$ $Petco Health and Wellness (WOOF.US)$ $Clearmind Medicine (CMND.US)$ $Innovative Eyewear (LUCY.US)$
📊⚡️📊
No comment yet